Delayed release composition for peroral administration
US12121614B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2023 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Apr 14, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.